PROBELPHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PROBELPHARMA
Largest movements
- Cash -€3,206
down €3,206 (-36.8%), from €8,719 to €5,514
mainly Net result for the year (-€3,556)
- Profit (loss) carried forward -€3,556
down €3,556 (-3.4%), from €103,440 to €99,884
- Gross operating margin -€616
down €616 (-18.9%), from -€3,265 to -€3,881
- Financial income +€500
up €500 (+49.7%), from €1,005 to €1,504
- Financial charges +€55
up €55 (+4.9%), from €1,124 to €1,179
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €296,278 | €293,072 | -€3,206 | -1.1% |
| Fixed assets | 21/28 | €287,060 | €287,060 | = | 0.0% |
| Financial fixed assets | 28 | €287,060 | €287,060 | = | 0.0% |
| Current assets | 29/58 | €9,217 | €6,012 | -€3,206 | -34.8% |
| Amounts receivable within one year | 40/41 | €498 | €498 | = | 0.0% |
| Other amounts receivable | 41 | €498 | €498 | = | 0.0% |
| Cash at bank and in hand | 54/58 | €8,719 | €5,514 | -€3,206 | -36.8% |
| Total equity and liabilities | 10/49 | €296,278 | €293,072 | -€3,206 | -1.1% |
| Equity | 10/15 | €123,914 | €120,358 | -€3,556 | -2.9% |
| Contributions | 10/11 | €16,481 | €16,481 | = | 0.0% |
| Reserves | 13 | €3,992 | €3,992 | = | 0.0% |
| Distributable reserves | 133 | €3,992 | €3,992 | = | 0.0% |
| Profit (loss) carried forward | 14 | €103,440 | €99,884 | -€3,556 | -3.4% |
| Amounts payable | 17/49 | €172,364 | €172,714 | +€350 | +0.2% |
| Amounts payable within one year | 42/48 | €172,364 | €172,714 | +€350 | +0.2% |
| Trade debts | 44 | €390 | €740 | +€350 | +89.9% |
| Suppliers | 440/4 | €390 | €740 | +€350 | +89.9% |
| Other amounts payable | 47/48 | €171,974 | €171,974 | = | 0.0% |
| Accrued charges and deferred income | 492/3 | €0 | - | = | |
| Other operating charges | 640/8 | €0 | - | = | |
| Gross operating margin | 9900 | -€3,265 | -€3,881 | -€616 | -18.9% |
| Operating profit (loss) | 9901 | -€3,265 | -€3,881 | -€616 | -18.9% |
| Financial income | 75/76B | €1,005 | €1,504 | +€500 | +49.7% |
| Recurring financial income | 75 | €1,005 | €1,504 | +€500 | +49.7% |
| Financial charges | 65/66B | €1,124 | €1,179 | +€55 | +4.9% |
| Recurring financial charges | 65 | €1,124 | €1,179 | +€55 | +4.9% |
| Profit (loss) for the period before taxes | 9903 | -€3,384 | -€3,556 | -€172 | -5.1% |
| Profit (loss) for the period | 9904 | -€3,384 | -€3,556 | -€172 | -5.1% |
| Profit (loss) for the period to be appropriated | 9905 | -€3,384 | -€3,556 | -€172 | -5.1% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 5 October 2026 via checked.be.